Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesA Decision-Theoretic Framework for the Application of Cost-Effectiveness Analysis in Regulatory Processes
PharmacoEconomics, 09/03/09
Baio G et al. – Cost–effectiveness analysis represents the most important tool in the health economics literature to quantify and qualify the reasoning behind the optimal decision process in terms of the allocation of resources to a given health intervention. However, the practical application of CEA in the regulatory process is often limited by some critical barriers, and decisions in clinical practice are frequently influenced by factors that do not contribute to efficient resource allocation, leading to inappropriate drug prescription and utilization.
Related Articles
Welfare properties of restrictions to health care based on cost effectiveness
Health Economics, 12/03/09
Relevance Score: 84%
Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis
Internal and Emergency Medicine, 11/10/09
Relevance Score: 84%
Cost-effectiveness of the Diabetes Care Protocol, a multifaceted computerized decision support diabetes management intervention that reduces cardiovascular risk
Diabetes Care, 11/30/09
Relevance Score: 80%
Cost-Effectiveness of the Boston Keratoprosthesis
American Journal of Ophthalmology, 11/25/09
Relevance Score: 80%
Cost-effectiveness analysis of rapid diagnostic test, microscopy and syndromic approach in the diagnosis of malaria in Nigeria: implications for scaling-up deployment of ACT
Malaria Journal, 11/24/09
Relevance Score: 80%
Today in Pharmacoeconomics...keeping you current
Receive free subspecialty "5-minute updates" via email
Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics
Journal of Clinical Pharmacy and Therapeutics, 03/19/10
Cost Effectiveness of Etoricoxib versus Celecoxib and Non-Selective NSAIDS in the Treatment of Ankylosing Spondylitis
PharmacoEconomics, 03/16/10
Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren
European Journal of Clinical Pharmacology, 03/16/10
Article Search
Sponsor
Sponsor